Matthew Etheridge
Foot Surgery · Pensacola, FLNPI 1093700494
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Musculoskeletal Transplant Foundation Inc. at 35.2% of the total. Reporting peaked in 2019 at $249 and has fallen 76.3% since, to $59 in 2025.
Across 19 payments — averaging $43.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Musculoskeletal Transplant Foundation Inc.$290
- Smith+Nephew$133
- Stability Biologics, LLC$87
- Merck$83
- Paratek Pharmaceuticals, Inc.$72
- Stryker$72
- plus $88 from 3 others
What the payments were for
- Food & beverage$81198%
- Education$142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Musculoskeletal Transplant Foundation Inc. | 2 | $290 |
| Smith+Nephew | 5 | $133 |
| Stability Biologics, LLC | 1 | $87 |
| Merck | 1 | $83 |
| Paratek Pharmaceuticals, Inc. | 5 | $72 |
| Stryker | 1 | $72 |
| Amgen | 2 | $36 |
| Solventum Corporation | 1 | $31 |
| GRT US Holding, Inc. | 1 | $20 |
How this compares
$825 in reported general payments places this provider in the 55th percentile of 107 foot surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Colchicine | 16 | $4,679 |
| Ciclopirox | 61 | $2,303 |
| Ammonium Lactate | 83 | $1,460 |
| Fluconazole | 102 | $1,359 |
| Cephalexin | 126 | $1,018 |
| Econazole Nitrate | 47 | $967 |
| Gabapentin | 43 | $868 |
| Terbinafine Hcl | 26 | $405 |
| Mupirocin | 52 | $375 |
| Doxycycline Hyclate | 27 | $305 |
| Ciprofloxacin Hcl | 27 | $305 |
| Diclofenac Sodium | 14 | $261 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 24 | $238 |
| Clotrimazole | 16 | $219 |
| Clindamycin Hcl | 39 | $208 |
Paid to pharmacies, not to this prescriber.
Other foot surgery in Pensacola
- Frank Castagna JrPensacola$532
- Larry HodsonPanama City$413K
- Bret BrennanTampa$60K
- Bradley HerbstJacksonville$20K
- Amy DunetzAventura$14K
- Than Binh NguyenTampa$13K
- Orlando CedenoJupiter$13K
- Karen LeePembroke Pines$12K
- Nicole GortaireSt Augustine$11K
- Alix CharlesPlantation$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.